Viamet Pharmaceuticals (Morrisville, NC) a pre-clinical stage pharmaceutical company focused on small-molecule inhibitors of metalloenzymes, closed a $18M Series B financing. Participants include Novartis Option Fund. Lilly Ventures, Intersouth Partners, Hatteras Venture Partners, Lurie Investment Fund and Astellas Venture Management.